Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17358096,relative bioavailability,Mean relative bioavailability calculated from plasma AUCs was 8.3% (SD 5.5%) for the monohydroxy derivative and 10.8% (SD 7.3%) for oxcarbazepine.,"Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358096/),%,8.3,7018,DB00776,Oxcarbazepine
,17358096,relative bioavailability,Mean relative bioavailability calculated from plasma AUCs was 8.3% (SD 5.5%) for the monohydroxy derivative and 10.8% (SD 7.3%) for oxcarbazepine.,"Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358096/),%,10.8,7019,DB00776,Oxcarbazepine
,3268334,absorption lag time,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),h,2.07,7366,DB00776,Oxcarbazepine
,3268334,absorption rate constant,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),1/[h],8.328,7367,DB00776,Oxcarbazepine
,3268334,apparent volume of distribution,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),[l] / [kg],3.937,7368,DB00776,Oxcarbazepine
,3268334,oral clearance,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),[l] / [kg],2.898,7369,DB00776,Oxcarbazepine
,3268334,elimination rate constant,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),1/[h],0.609,7370,DB00776,Oxcarbazepine
,3268334,half-life,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),h,1.26,7371,DB00776,Oxcarbazepine
,3268334,formation rate constant,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),1/[h],0.593,7372,DB00776,Oxcarbazepine
,3268334,elimination rate constant,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),1/[h],0.082,7373,DB00776,Oxcarbazepine
,3268334,half-life,"Calculated pharmacokinetic parameter values for the drug, assuming complete oral bioavailability, were: absorption lag time 2.07 +/- 1.61 h: absorption rate constant 8.328 +/- 8.941 h-1: apparent volume of distribution 3.937 +/- 2.222 L kg-1: oral clearance 2.898 +/- 1.439 L kg-1: elimination rate constant 0.609 +/- 0.261 h-1 (half-life 1.26 +/- 0.37 h), while the metabolite had a formation rate constant of 0.593 +/- 0.233 h-1, and an elimination rate constant of 0.082 +/- 0.014 h-1 (half-life 8.74 +/- 1.79 h).",Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3268334/),h,8.74,7374,DB00776,Oxcarbazepine
,24123382,flow rate,"The separation of oxcarbazepine and the MHD enantiomers was obtained on a chiral phase Chiralcel OD-H column, using a mixture of hexane:ethanol:isopropanol (80:15:5, v/v/v) as mobile phase at a flow rate of 1.3 mL/min with a split ratio of 1:5, and quantification was performed by LC-MS/MS.",Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),[ml] / [min],1.3,9265,DB00776,Oxcarbazepine
,24123382,maximum plasma concentration,The maximum plasma concentration of oxcarbazepine was 1.2 µg/mL at 0.75 h.,Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),[μg] / [ml],1.2,9266,DB00776,Oxcarbazepine
,24123382,AUC(0-12),"The kinetic disposition of MHD is enantioselective, with a higher proportion of the S-(+)-MHD enantiomer compared to R-(-)-MHD and an AUC(0-12) S-(+)/R-(-) ratio of 5.44.",Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),,5.44,9267,DB00776,Oxcarbazepine
,24123382,ratio,"The kinetic disposition of MHD is enantioselective, with a higher proportion of the S-(+)-MHD enantiomer compared to R-(-)-MHD and an AUC(0-12) S-(+)/R-(-) ratio of 5.44.",Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24123382/),,5.44,9268,DB00776,Oxcarbazepine
,27595590,apparent clearance,"Population PK results from 152 adolescent patients revealed a perampanel apparent clearance of 0.729L/h, consistent with previous analyses in adolescents and adults.","Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27595590/),[l] / [h],0.729,12175,DB00776,Oxcarbazepine
,28528287,Clearance,Clearance estimates (95% CI) were 84.9L/h (69.5-100.3) for oxcarbazepine and 2.0L/h (1.9-2.1) for both MHD enantiomers.,Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),[l] / [h],84.9,15058,DB00776,Oxcarbazepine
,28528287,Clearance,Clearance estimates (95% CI) were 84.9L/h (69.5-100.3) for oxcarbazepine and 2.0L/h (1.9-2.1) for both MHD enantiomers.,Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),[l] / [h],2.0,15059,DB00776,Oxcarbazepine
,28528287,volume of distribution,"The volume of distribution was much larger for oxcarbazepine (131L (97-165)) as compared to R-(-)- and S-(+)-MHD (23.6L (14.4-32.8) vs. 31.7L (22.5-40.9), respectively).",Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),l,131,15060,DB00776,Oxcarbazepine
,28528287,volume of distribution,"The volume of distribution was much larger for oxcarbazepine (131L (97-165)) as compared to R-(-)- and S-(+)-MHD (23.6L (14.4-32.8) vs. 31.7L (22.5-40.9), respectively).",Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),l,23.6,15061,DB00776,Oxcarbazepine
,28528287,volume of distribution,"The volume of distribution was much larger for oxcarbazepine (131L (97-165)) as compared to R-(-)- and S-(+)-MHD (23.6L (14.4-32.8) vs. 31.7L (22.5-40.9), respectively).",Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),l,31.7,15062,DB00776,Oxcarbazepine
,16404803,Milk/maternal plasma concentration ratios,"Milk/maternal plasma concentration ratios close to 1 demonstrate extensive transfer to breast milk of many AEDs including ethosuximide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, and zonisamide.",Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404803/),,1,16688,DB00776,Oxcarbazepine
,11868969,t(max),"3. In an atypical reaction for oximes, BIA 2-024 in rats was rapidly (t(max) = 2h) metabolized to the non-active 10-nitro-derivative (BIA 2-254), whereas rabbits and particularly mice oxidized the oxime moiety to a much lower extent.","Metabolism of 10,11-dihydro-10-hydroxyimino-5H-dibenz/b, f/azepine-5-carboxamide, a potent anti-epileptic drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868969/),h,2,29717,DB00776,Oxcarbazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,105.15,35400,DB00776,Oxcarbazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,84.76,35401,DB00776,Oxcarbazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,94.45,35402,DB00776,Oxcarbazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,96.52,35403,DB00776,Oxcarbazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,98.62,35404,DB00776,Oxcarbazepine
,12008131,absolute recoveries,"Quantization limits of oxcarbazepine, 10-hydroxycarbamazepine, epoxycarbamazepine, carbamazepine, phenobarbital and phenytoïn are 0.58, 3.5, 2.35, 0.66, 1.02 and 3.13 microg/ml, respectively, and absolute recoveries are 105.15, 84.76, 94.45, 96.52, 98.62 and 95.08%, respectively.",LC determination of oxcarbazepine and its active metabolite in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12008131/),%,95.08,35405,DB00776,Oxcarbazepine
>,12959634,bioavailability,The bioavailability of the oral formulation of oxcarbazepine is high (>95%).,Clinical pharmacokinetics of oxcarbazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,95,36869,DB00776,Oxcarbazepine
,12959634,plasma protein binding,The plasma protein binding of MHD is about 40%.,Clinical pharmacokinetics of oxcarbazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,40,36870,DB00776,Oxcarbazepine
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,1-5,36871,DB00776,Oxcarbazepine
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,7-20,36872,DB00776,Oxcarbazepine
,10613609,area under the serum concentration versus time curve,The area under the serum concentration versus time curve of S-10-hydroxycarbazepine was about fivefold greater than that of R-10-hydroxycarbazepine (129.8 +/- 33.1 versus 26.3 +/- 8.5 mg/L x h; P < .001).,Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613609/),[mg] / [h·l],129.8,41301,DB00776,Oxcarbazepine
,10613609,area under the serum concentration versus time curve,The area under the serum concentration versus time curve of S-10-hydroxycarbazepine was about fivefold greater than that of R-10-hydroxycarbazepine (129.8 +/- 33.1 versus 26.3 +/- 8.5 mg/L x h; P < .001).,Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613609/),[mg] / [h·l],26.3,41302,DB00776,Oxcarbazepine
,10613609,Half-lives,Half-lives did not differ significantly between the enantiomers (11.9 +/- 3.3 hours for R-10-hydroxycarbazepine versus 13.0 +/- 4.1 hours for S-10-hydroxycarbazepine).,Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613609/),h,11.9,41303,DB00776,Oxcarbazepine
,10613609,Half-lives,Half-lives did not differ significantly between the enantiomers (11.9 +/- 3.3 hours for R-10-hydroxycarbazepine versus 13.0 +/- 4.1 hours for S-10-hydroxycarbazepine).,Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613609/),h,13.0,41304,DB00776,Oxcarbazepine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1404,43042,DB00776,Oxcarbazepine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1374,43043,DB00776,Oxcarbazepine
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1400,43044,DB00776,Oxcarbazepine
,18781906,trough levels,"Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],477,43045,DB00776,Oxcarbazepine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],240,43046,DB00776,Oxcarbazepine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],351,43047,DB00776,Oxcarbazepine
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],356,43048,DB00776,Oxcarbazepine
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],2.9,44201,DB00776,Oxcarbazepine
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],5.1,44202,DB00776,Oxcarbazepine
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],89,44203,DB00776,Oxcarbazepine
,12959317,AUC,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),[h·μg] / [ml],119,44204,DB00776,Oxcarbazepine
,12959317,half-lives,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),h,17,44205,DB00776,Oxcarbazepine
,12959317,half-lives,"In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS).",The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959317/),h,20,44206,DB00776,Oxcarbazepine
,8451779,bioavailability,"This reduction in FEL bioavailability is much smaller than that observed after co-administration of carbamazepine (CBZ) (i.e., 94%).",Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451779/),%,94,49762,DB00776,Oxcarbazepine
,26818624,saliva/plasma MHD ratio,"The saliva/plasma MHD ratio was around 0.71 and had no significant difference with age, gender, and combined medications.",Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26818624/),,0.71,51461,DB00776,Oxcarbazepine
,29169112,free fraction at the time of peak plasma concentration,"The free fraction at the time of peak plasma concentration of OXC was 0.27 for OXC, 0.37 for S-(+)-MHD and 0.42 for R-(-)-MHD.",Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29169112/),,0.27,52378,DB00776,Oxcarbazepine
,29169112,free fraction at the time of peak plasma concentration,"The free fraction at the time of peak plasma concentration of OXC was 0.27 for OXC, 0.37 for S-(+)-MHD and 0.42 for R-(-)-MHD.",Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29169112/),,0.37,52379,DB00776,Oxcarbazepine
,29169112,free fraction at the time of peak plasma concentration,"The free fraction at the time of peak plasma concentration of OXC was 0.27 for OXC, 0.37 for S-(+)-MHD and 0.42 for R-(-)-MHD.",Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29169112/),,0.42,52380,DB00776,Oxcarbazepine
,26924357,maximal encapsulation,Nano-spherical OX-emulsomes with maximal encapsulation of 96.75% were generated.,Identifying lipidic emulsomes for improved oxcarbazepine brain targeting: In vitro and rat in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26924357/),,96,54358,DB00776,Oxcarbazepine
lower,24050973,brain/plasma ratios,"All the test compounds presented brain/plasma ratios lower than 1.0, suggesting that the blood-brain barrier restricts drug entry into the brain.","Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24050973/),,1.0,56614,DB00776,Oxcarbazepine
>,24050973,brain/plasma ratios,"In agreement with in vitro studies already performed within our research group, CBZ, CBZ-10,11-epoxide and oxcarbazepine exhibited the highest brain/plasma ratios (>0.50), followed by eslicarbazepine, R-licarbazepine, trans-diol and BIA 2-024 (ratios within 0.05-0.50).","Pharmacokinetics, brain distribution and plasma protein binding of carbamazepine and nine derivatives: new set of data for predictive in silico ADME models. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24050973/),,0.50,56615,DB00776,Oxcarbazepine
,18397682,CL/F,"Eslicarbazepine CL/F and CLR were, respectively, 3.40 l/h and 1.04 l/h (17.3 ml/min) in the control group, and 2.10 l/h (35.0 ml/min) and 0.61 l/h (10.2 ml/min) in the mild, 1.60 l/h (26.7 ml/min) and 0.22 l/h (3.7 ml/min) in the moderate, and 1.33 l/h (21.2 ml/min) and 0.09 l/h (1.5 ml/min) in the severe renal impairment groups.",Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397682/),[l] / [h],3.40,61040,DB00776,Oxcarbazepine
,18397682,CL/F,"Eslicarbazepine CL/F and CLR were, respectively, 3.40 l/h and 1.04 l/h (17.3 ml/min) in the control group, and 2.10 l/h (35.0 ml/min) and 0.61 l/h (10.2 ml/min) in the mild, 1.60 l/h (26.7 ml/min) and 0.22 l/h (3.7 ml/min) in the moderate, and 1.33 l/h (21.2 ml/min) and 0.09 l/h (1.5 ml/min) in the severe renal impairment groups.",Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397682/),[l] / [h],2.10,61041,DB00776,Oxcarbazepine
,18397682,CL/F,"Eslicarbazepine CL/F and CLR were, respectively, 3.40 l/h and 1.04 l/h (17.3 ml/min) in the control group, and 2.10 l/h (35.0 ml/min) and 0.61 l/h (10.2 ml/min) in the mild, 1.60 l/h (26.7 ml/min) and 0.22 l/h (3.7 ml/min) in the moderate, and 1.33 l/h (21.2 ml/min) and 0.09 l/h (1.5 ml/min) in the severe renal impairment groups.",Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397682/),[l] / [h],1.60,61042,DB00776,Oxcarbazepine
,18397682,CL/F,"Eslicarbazepine CL/F and CLR were, respectively, 3.40 l/h and 1.04 l/h (17.3 ml/min) in the control group, and 2.10 l/h (35.0 ml/min) and 0.61 l/h (10.2 ml/min) in the mild, 1.60 l/h (26.7 ml/min) and 0.22 l/h (3.7 ml/min) in the moderate, and 1.33 l/h (21.2 ml/min) and 0.09 l/h (1.5 ml/min) in the severe renal impairment groups.",Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397682/),[l] / [h],1.33,61043,DB00776,Oxcarbazepine
,18397682,CLR,"Eslicarbazepine CL/F and CLR were, respectively, 3.40 l/h and 1.04 l/h (17.3 ml/min) in the control group, and 2.10 l/h (35.0 ml/min) and 0.61 l/h (10.2 ml/min) in the mild, 1.60 l/h (26.7 ml/min) and 0.22 l/h (3.7 ml/min) in the moderate, and 1.33 l/h (21.2 ml/min) and 0.09 l/h (1.5 ml/min) in the severe renal impairment groups.",Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397682/),[l] / [h],1.04,61044,DB00776,Oxcarbazepine
,18397682,CLR,"Eslicarbazepine CL/F and CLR were, respectively, 3.40 l/h and 1.04 l/h (17.3 ml/min) in the control group, and 2.10 l/h (35.0 ml/min) and 0.61 l/h (10.2 ml/min) in the mild, 1.60 l/h (26.7 ml/min) and 0.22 l/h (3.7 ml/min) in the moderate, and 1.33 l/h (21.2 ml/min) and 0.09 l/h (1.5 ml/min) in the severe renal impairment groups.",Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397682/),[l] / [h],0.22,61045,DB00776,Oxcarbazepine
,18397682,CLR,"Eslicarbazepine CL/F and CLR were, respectively, 3.40 l/h and 1.04 l/h (17.3 ml/min) in the control group, and 2.10 l/h (35.0 ml/min) and 0.61 l/h (10.2 ml/min) in the mild, 1.60 l/h (26.7 ml/min) and 0.22 l/h (3.7 ml/min) in the moderate, and 1.33 l/h (21.2 ml/min) and 0.09 l/h (1.5 ml/min) in the severe renal impairment groups.",Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397682/),[l] / [h],1.33,61046,DB00776,Oxcarbazepine
,18397682,CLR,"Eslicarbazepine CL/F and CLR were, respectively, 3.40 l/h and 1.04 l/h (17.3 ml/min) in the control group, and 2.10 l/h (35.0 ml/min) and 0.61 l/h (10.2 ml/min) in the mild, 1.60 l/h (26.7 ml/min) and 0.22 l/h (3.7 ml/min) in the moderate, and 1.33 l/h (21.2 ml/min) and 0.09 l/h (1.5 ml/min) in the severe renal impairment groups.",Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18397682/),[l] / [h],0.09,61047,DB00776,Oxcarbazepine
,26514967,AUC(0-12),The kinetic disposition of MHD was enantioselective with plasma accumulation (AUC(0-12) S-(+)/R-(-) ratio of 4.38) and lower fraction unbound (0.37 vs 0.42) of the S-(+)-MHD enantiomer.,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),,4.38,66710,DB00776,Oxcarbazepine
,26514967,fraction unbound,The kinetic disposition of MHD was enantioselective with plasma accumulation (AUC(0-12) S-(+)/R-(-) ratio of 4.38) and lower fraction unbound (0.37 vs 0.42) of the S-(+)-MHD enantiomer.,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),,0.37,66711,DB00776,Oxcarbazepine
,26514967,fraction unbound,The kinetic disposition of MHD was enantioselective with plasma accumulation (AUC(0-12) S-(+)/R-(-) ratio of 4.38) and lower fraction unbound (0.37 vs 0.42) of the S-(+)-MHD enantiomer.,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),,0.42,66712,DB00776,Oxcarbazepine
,26514967,mean residence time,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),h,4.91,66713,DB00776,Oxcarbazepine
,26514967,mean residence time,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),h,4.20,66714,DB00776,Oxcarbazepine
,26514967,apparent volume of distribution,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[l] / [kg],4.72,66715,DB00776,Oxcarbazepine
,26514967,apparent volume of distribution,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[l] / [kg],3.15,66716,DB00776,Oxcarbazepine
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],2.65,66717,DB00776,Oxcarbazepine
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],2.98,66718,DB00776,Oxcarbazepine
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],10.15,66719,DB00776,Oxcarbazepine
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],11.60,66720,DB00776,Oxcarbazepine
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],1.98,66721,DB00776,Oxcarbazepine
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],2.18,66722,DB00776,Oxcarbazepine
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],8.10,66723,DB00776,Oxcarbazepine
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],8.83,66724,DB00776,Oxcarbazepine
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],23.79,66725,DB00776,Oxcarbazepine
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],26.19,66726,DB00776,Oxcarbazepine
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],97.87,66727,DB00776,Oxcarbazepine
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],108.35,66728,DB00776,Oxcarbazepine
,26751267,total C/D ratio,"The interindividual pharmacokinetic variability was extensive, as illustrated by a 100-fold variability in serum concentration compared with dose (total C/D ratio 0.03-3.29 µmol·L·mg).",Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26751267/),l·mg·μM,0.03-3.29,70769,DB00776,Oxcarbazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.32,73970,DB00776,Oxcarbazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.34,73971,DB00776,Oxcarbazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.45,73972,DB00776,Oxcarbazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.46,73973,DB00776,Oxcarbazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.52,73974,DB00776,Oxcarbazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.53,73975,DB00776,Oxcarbazepine
,14639055,LDR,"The median LDR of LEV was 0.32 for LEV + phenytoin, 0.32 for LEV + carbamazepine, 0.34 LEV + oxcarbazepine, 0.45 for LEV + lamotrigine, 0.46 for LEV + phenobarital, 0.52 for LEV monotherapy, 0.53 for LEV + valproic acid, and 0.54 LEV + valproic acid + lamotrigine.",Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14639055/),,0.54,73976,DB00776,Oxcarbazepine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.52,74496,DB00776,Oxcarbazepine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],2.17,74497,DB00776,Oxcarbazepine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.803,74498,DB00776,Oxcarbazepine
,26908152,CL/F,"For a typical patient with CLcr of 90 mL/min and DOSE of 100mg, co-medication with PHT, CBZ, OXC, and PB increased the CL/F to 2.52 (1.16+1.36)L/h, 2.17 (1.16+1.01)L/h, 1.803 (1.16+0.643)L/h, and 1.636 (1.16+0.476)L/h, respectively, which was 117, 87, 55, and 41% higher, respectively, than in patients without co-medication.",Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26908152/),[l] / [h],1.636,74499,DB00776,Oxcarbazepine
,25220641,Ka,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),1/[h],0.83,82170,DB00776,Oxcarbazepine
,25220641,Vd,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [kg],0.67,82171,DB00776,Oxcarbazepine
,25220641,CL,"The population values of pharmacokinetic parameters estimated in the final model were as follows: Ka=0.83 h-1, Vd=0.67 L/kg, and CL=0.035 L·kg(-1)·h(-1).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[l] / [h·kg],0.035,82172,DB00776,Oxcarbazepine
,25220641,MP,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.01,82173,DB00776,Oxcarbazepine
,25220641,MAE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),[mg] / [l],0.46,82174,DB00776,Oxcarbazepine
,25220641,MSE,"For the final model, the evaluation results (95% CI) were MPE=0.01 (-0.07-0.10) mg/L, MAE=0.46 (0.40-0.51) mg/L, MSE=0.39 (0.27-0.51) (mg/L)(2).",Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220641/),,0.39,82175,DB00776,Oxcarbazepine
,18175970,flow rate,"Chromatographic separation was achieved isocratically on a C18 reversed-phase column within 3.0 min, using a mobile phase of acetonitrile-10 mM ammonium formate (90 : 10 v/v) at a flow rate of 0.3 ml/min.",Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),[ml] / [min],0.3,87504,DB00776,Oxcarbazepine
>,18175970,m/z,Quantitation was achieved using multiple reaction monitoring (MRM) scan at MRM transitions m/z 253>208 and m/z 281>86 for OXB and the IS respectively.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),,253,87505,DB00776,Oxcarbazepine
>,18175970,m/z,Quantitation was achieved using multiple reaction monitoring (MRM) scan at MRM transitions m/z 253>208 and m/z 281>86 for OXB and the IS respectively.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),,208,87506,DB00776,Oxcarbazepine
>,18175970,m/z 281,Quantitation was achieved using multiple reaction monitoring (MRM) scan at MRM transitions m/z 253>208 and m/z 281>86 for OXB and the IS respectively.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),,86,87507,DB00776,Oxcarbazepine
,18175970,recoveries,Analytical recoveries of OXB from spiked human plasma were in the range of 74.9 to 76.3%.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),%,74.9 to 76.3,87508,DB00776,Oxcarbazepine
,16197654,Plasma drug concentrations,"Plasma drug concentrations after 24 hours without medication were 4.1 mg/L for CBZ-ERC, 8 mg/L for 600 mg OXC, and 16 mg/L for 1200 mg OXC.",Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197654/),[mg] / [l],4.1,103001,DB00776,Oxcarbazepine
,16197654,Plasma drug concentrations,"Plasma drug concentrations after 24 hours without medication were 4.1 mg/L for CBZ-ERC, 8 mg/L for 600 mg OXC, and 16 mg/L for 1200 mg OXC.",Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197654/),[mg] / [l],8,103002,DB00776,Oxcarbazepine
,16197654,Plasma drug concentrations,"Plasma drug concentrations after 24 hours without medication were 4.1 mg/L for CBZ-ERC, 8 mg/L for 600 mg OXC, and 16 mg/L for 1200 mg OXC.",Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197654/),[mg] / [l],16,103003,DB00776,Oxcarbazepine
,16197654,steady-state trough,"If a patient was to take only a single dose 24 hours late, it would take 24 hours to reach steady-state trough values for CBZ-ERC, 36 hours for 600 mg OXC, and 2 days for 1200 mg OXC.",Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197654/),h,36,103004,DB00776,Oxcarbazepine
,16197654,steady-state trough,"If a patient was to take only a single dose 24 hours late, it would take 24 hours to reach steady-state trough values for CBZ-ERC, 36 hours for 600 mg OXC, and 2 days for 1200 mg OXC.",Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16197654/),d,2,103005,DB00776,Oxcarbazepine
,8992022,peak concentrations,Plasma concentrations reached peak concentrations of 2.4-8.8 micrograms/mliter at about 1.5 h and declined with an elimination half-life of approximately 4 h.,Pharmacokinetics of oxcarbazepine in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992022/),[μg] / [mliter],2.4-8.8,103112,DB00776,Oxcarbazepine
,8992022,elimination half-life,Plasma concentrations reached peak concentrations of 2.4-8.8 micrograms/mliter at about 1.5 h and declined with an elimination half-life of approximately 4 h.,Pharmacokinetics of oxcarbazepine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992022/),h,4,103113,DB00776,Oxcarbazepine
,8992022,terminal half-life,"Plasma concentrations showed a pronounced decline from day 3, and the terminal half-life decreased to 2 h and 1 h.",Pharmacokinetics of oxcarbazepine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992022/),h,2,103114,DB00776,Oxcarbazepine
,8992022,terminal half-life,"Plasma concentrations showed a pronounced decline from day 3, and the terminal half-life decreased to 2 h and 1 h.",Pharmacokinetics of oxcarbazepine in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992022/),h,1,103115,DB00776,Oxcarbazepine
,15286095,t(max),"Median maximum plasma concentrations of the major metabolite (licarbazepine, (+/-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide) were attained (t(max)) at 2 to 3 h postdose; thereafter, plasma concentrations declined with a mean apparent terminal half-life of 9 to 13 h following repeated dosing.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),h,2 to 3,105427,DB00776,Oxcarbazepine
,15286095,apparent terminal half-life,"Median maximum plasma concentrations of the major metabolite (licarbazepine, (+/-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide) were attained (t(max)) at 2 to 3 h postdose; thereafter, plasma concentrations declined with a mean apparent terminal half-life of 9 to 13 h following repeated dosing.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),h,9 to 13,105428,DB00776,Oxcarbazepine
,15286095,extent of accumulation (R(O),"Licarbazepine accumulated in plasma following repeated administration of BIA 2-093; the mean extent of accumulation (R(O), calculated from AUC(0-tau) (day 8)/AUC(0-tau) (day 1)) was 3.0 after repeated, twice-daily dosing and 1.4 to 1.7 after once-daily dosing.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),,3.0,105429,DB00776,Oxcarbazepine
,15286095,extent of accumulation (R(O),"Licarbazepine accumulated in plasma following repeated administration of BIA 2-093; the mean extent of accumulation (R(O), calculated from AUC(0-tau) (day 8)/AUC(0-tau) (day 1)) was 3.0 after repeated, twice-daily dosing and 1.4 to 1.7 after once-daily dosing.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),,1.4 to 1.7,105430,DB00776,Oxcarbazepine
,15286095,half-life,"Steady-state plasma licarbazepine concentrations were attained at 4 to 5 days of once- or twice-daily dosing, consistent with an effective half-life on the order of 20 to 24 h.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),h,20 to 24,105431,DB00776,Oxcarbazepine
,15286095,renal clearance,"The mean renal clearance of licarbazepine from plasma was approximately 20 to 30 mL/min, which is low compared with the glomerular filtration rate.","Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),[ml] / [min],20 to 30,105432,DB00776,Oxcarbazepine
,15286095,total amount,The total amount of licarbazepine recovered in urine was approximately 20% within 12 h postdose and 40% within 24 h postdose.,"Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),%,20,105433,DB00776,Oxcarbazepine
,15286095,total amount,The total amount of licarbazepine recovered in urine was approximately 20% within 12 h postdose and 40% within 24 h postdose.,"Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15286095/),%,40,105434,DB00776,Oxcarbazepine
over,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,30,106800,DB00776,Oxcarbazepine
,10612356,elimination half-lives,"The route of elimination differs to an important extent from one compound to another, and elimination half-lives range from over 30 h for zonisamide to 5-7 h for gabapentin.",The clinical pharmacokinetics of the new antiepileptic drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10612356/),h,5-7,106801,DB00776,Oxcarbazepine
,9008266,bound concentration,"The mean bound concentration ranged from 37 to 40%; however, an affinity of MHD to red corpuscles was found.",The distribution of 10-hydroxy carbazepine in blood compartments. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9008266/),%,37 to 40,115665,DB00776,Oxcarbazepine
,25151742,trough concentrations,Seven sampling designs were investigated using various number of trough concentrations per individual ranging from 1-4.,[Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25151742/),,1-4,126413,DB00776,Oxcarbazepine
,8557788,flow rate,The eluting solvent was 20% acetonitrile in water at a flow rate of 1.5 ml/min and the detector was monitored at 215 nm.,Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557788/),[ml] / [min],1.5,130568,DB00776,Oxcarbazepine
,8557788,detection limit,"The detection limit of OXC and 10-hydroxycarbazepine was 50 and 20 ng/ml, respectively.",Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557788/),[ng] / [ml],50,130569,DB00776,Oxcarbazepine
,8557788,detection limit,"The detection limit of OXC and 10-hydroxycarbazepine was 50 and 20 ng/ml, respectively.",Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557788/),[ng] / [ml],20,130570,DB00776,Oxcarbazepine
,8557788,relative,The relative and absolute recoveries varied between 71.4% and 104.0%.,Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557788/),%,71.4,130571,DB00776,Oxcarbazepine
,8557788,absolute recoveries,The relative and absolute recoveries varied between 71.4% and 104.0%.,Rapid micromethod for simultaneous measurement of oxcarbazepine and its active metabolite in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8557788/),%,104.0,130572,DB00776,Oxcarbazepine
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],4.41,134944,DB00776,Oxcarbazepine
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],7.23,134945,DB00776,Oxcarbazepine
,29210977,CL/F,"The mean (±SD) of LEV CL/F in group A (n = 180), B (n = 92), and C (n = 58) was 4.41 ± 2.06 L/h, 7.23 ± 3.72 L/h, and 4.87 ± 1.65 L/h, respectively.",Influence of Comedication on Levetiracetam Pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[l] / [h],4.87,134946,DB00776,Oxcarbazepine
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],17.30,134947,DB00776,Oxcarbazepine
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],20.08,134948,DB00776,Oxcarbazepine
,29210977,C0,LEV C0 values were significantly lower in the EIAEDs group than in the monotherapy group (17.30 ± 7.77 versus 20.08 ± 9.69 mcg/mL; P = 0.038) or indeed the NEIAEDs group (17.30 ± 7.77 versus 20.49 ± 9.46 mcg/mL; P = 0.027).,Influence of Comedication on Levetiracetam Pharmacokinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29210977/),[mcg] / [ml],20.49,134949,DB00776,Oxcarbazepine
,24549964,flow,"Sample preparation was accomplished through protein precipitation with methanol, and chromatographic separation was performed on an Acquity BEH C18 column (2.1 mm×50 mm, 1.7 μm) with gradient profile at a flow of 0.45 mL/min.",Rapid and sensitive UPLC-MS/MS method for the determination of domperidone in human plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24549964/),[ml] / [min],0.,135255,DB00776,Oxcarbazepine
,8156973,half-life,MHD is eliminated with a half-life of about 8-10 h.,Clinical pharmacology and pharmacokinetics of oxcarbazepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8156973/),h,8-10,135672,DB00776,Oxcarbazepine
,30636182,clearance (CL/F),"The typical values for MHD clearance (CL/F), distribution volume (V/F) and absorption rate constant (Ka) were 3.25 L/h/70 kg, 151.41 L/70 kg and 0.598 h-1 , respectively.",Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636182/),[l] / [70·h·kg],3.25,136555,DB00776,Oxcarbazepine
,30636182,distribution volume (V/F),"The typical values for MHD clearance (CL/F), distribution volume (V/F) and absorption rate constant (Ka) were 3.25 L/h/70 kg, 151.41 L/70 kg and 0.598 h-1 , respectively.",Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636182/),[l] / [70·kg],151.41,136556,DB00776,Oxcarbazepine
,30636182,absorption rate constant (Ka),"The typical values for MHD clearance (CL/F), distribution volume (V/F) and absorption rate constant (Ka) were 3.25 L/h/70 kg, 151.41 L/70 kg and 0.598 h-1 , respectively.",Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30636182/),1/[h],0.598,136557,DB00776,Oxcarbazepine
,12952496,apparent terminal half-life,"Maximum plasma concentrations (C(max)) of BIA 2-005 and oxcarbazepine were reached, respectively, at 0.75-4h and 6h postdose, after which they declined with an approximate mean apparent terminal half-life of 8-17h and 7-12h, respectively.","Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12952496/),h,8-17,141848,DB00776,Oxcarbazepine
,12952496,apparent terminal half-life,"Maximum plasma concentrations (C(max)) of BIA 2-005 and oxcarbazepine were reached, respectively, at 0.75-4h and 6h postdose, after which they declined with an approximate mean apparent terminal half-life of 8-17h and 7-12h, respectively.","Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12952496/),h,7-12,141849,DB00776,Oxcarbazepine
,12952496,Renal clearance,"Renal clearance of BIA 2-005 (20 mL/min) appeared to be constant over the dose range studied, indicating that the dose-dependent urinary recovery was due either to increased formation of BIA 2-005 with increasing dose level or to decreased non-renal elimination of the metabolite.","Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12952496/),[ml] / [min],20,141850,DB00776,Oxcarbazepine
,17616250,flow rate,"The chromatographic separation was performed by isocratic elution with water/methanol (88:12, v/v), pumped at a flow rate of 0.7 mL min(-1), on a LichroCART 250-4 ChiraDex (beta-cyclodextrin, 5 microm) column at 30 degrees C.","Simultaneous and enantioselective liquid chromatographic determination of eslicarbazepine acetate, S-licarbazepine, R-licarbazepine and oxcarbazepine in mouse tissue samples using ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17616250/),[ml] / [min],0.7,142710,DB00776,Oxcarbazepine
,1742552,flow rate,Chromatographic separation of oxcarbazepine and its metabolites was achieved using a mobile phase consisting of acetonitrile/methanol/water (13:25:62 by volume) at a flow rate of 1.2 mL/min in conjunction with a Waters Associates Nova-Pak C18 column.,Solid phase extraction of oxcarbazepine and its metabolites from plasma for analysis by high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742552/),[ml] / [min],1.2,155968,DB00776,Oxcarbazepine
,2015172,Elimination half-lives,4. Elimination half-lives (mean +/- s.e. mean) of 10-OH-CZ were unaltered by 2 weeks' therapy with OXC (before 11.3 +/- 1.1 h; after 13.9 +/- 3 h).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),h,11.3,156873,DB00776,Oxcarbazepine
,2015172,Elimination half-lives,4. Elimination half-lives (mean +/- s.e. mean) of 10-OH-CZ were unaltered by 2 weeks' therapy with OXC (before 11.3 +/- 1.1 h; after 13.9 +/- 3 h).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),h,13.9,156874,DB00776,Oxcarbazepine
,2015172,Trough plasma concentrations,Trough plasma concentrations of 10-OH-CZ at steady-state (31 +/- 2.2 mumol l-1) were higher than predicted (16.5 +/- 4 mumol l-1).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),[μM] / [l],31,156875,DB00776,Oxcarbazepine
,2015172,Trough plasma concentrations,Trough plasma concentrations of 10-OH-CZ at steady-state (31 +/- 2.2 mumol l-1) were higher than predicted (16.5 +/- 4 mumol l-1).,Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015172/),[μM] / [l],16.5,156876,DB00776,Oxcarbazepine
,23995050,maximum Cl/F,"Age was a significant factor contributing to pharmacokinetic variability in individuals using LTG, OXC, and CBZ with increasing clearance as a function of bioavailability (Cl/F) over age 18, a maximum Cl/F at 33years (CBZ) and 36 years (LTG and OXC), and a gradual decrease of Cl/F towards older age.",The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23995050/),years,33,170622,DB00776,Oxcarbazepine
,23995050,maximum Cl/F,"Age was a significant factor contributing to pharmacokinetic variability in individuals using LTG, OXC, and CBZ with increasing clearance as a function of bioavailability (Cl/F) over age 18, a maximum Cl/F at 33years (CBZ) and 36 years (LTG and OXC), and a gradual decrease of Cl/F towards older age.",The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23995050/),years,36,170623,DB00776,Oxcarbazepine
,29171002,apparent clearance (CL/F),"In the absence of antiepileptic drugs (AEDs) affecting perampanel PK, estimated perampanel apparent clearance (CL/F) was 0.668 L/h (all subjects) and 0.682 L/h (adolescent subjects).",Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29171002/),[l] / [h],0.668,172319,DB00776,Oxcarbazepine
,29171002,apparent clearance (CL/F),"In the absence of antiepileptic drugs (AEDs) affecting perampanel PK, estimated perampanel apparent clearance (CL/F) was 0.668 L/h (all subjects) and 0.682 L/h (adolescent subjects).",Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29171002/),[l] / [h],0.682,172320,DB00776,Oxcarbazepine
,28771787,trough concentration (Ctrough ),A parent-metabolite population pharmacokinetic model in children was developed to evaluate the consistency between the recommended paediatric doses and the reference range for trough concentration (Ctrough ) of MHD (3-35 mg l-1 ).,Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[mg] / [l],3-35,176046,DB00776,Oxcarbazepine
,28771787,Ctrough,The probability to obtain Ctrough between 3-35 mg l-1 was determined by Monte Carlo simulations for doses ranging from 10 to 90 mg kg-1 day-1 .,Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[mg] / [l],3-35,176047,DB00776,Oxcarbazepine
,28771787,clearance,"Typical values for oxcarbazepine clearance, central and peripheral distribution volume and distribution clearance were 140 l h-1 70 kg-1 , 337 l 70 kg-1 , 60.7 l and 62.5 l h-1 , respectively.",Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[l] / [70·h·kg],140,176048,DB00776,Oxcarbazepine
,28771787,peripheral distribution volume,"Typical values for oxcarbazepine clearance, central and peripheral distribution volume and distribution clearance were 140 l h-1 70 kg-1 , 337 l 70 kg-1 , 60.7 l and 62.5 l h-1 , respectively.",Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[l] / [70·kg],337,176049,DB00776,Oxcarbazepine
,28771787,peripheral distribution volume,"Typical values for oxcarbazepine clearance, central and peripheral distribution volume and distribution clearance were 140 l h-1 70 kg-1 , 337 l 70 kg-1 , 60.7 l and 62.5 l h-1 , respectively.",Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),l,60.7,176050,DB00776,Oxcarbazepine
,28771787,distribution clearance,"Typical values for oxcarbazepine clearance, central and peripheral distribution volume and distribution clearance were 140 l h-1 70 kg-1 , 337 l 70 kg-1 , 60.7 l and 62.5 l h-1 , respectively.",Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[l] / [h],62.5,176051,DB00776,Oxcarbazepine
,28771787,clearance,Typical values for MHD clearance and distribution volume were 4.11 l h-1 70 kg-1 and 54.8 l 70 kg-1 respectively.,Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[l] / [70·h·kg],4.11,176052,DB00776,Oxcarbazepine
,28771787,distribution volume,Typical values for MHD clearance and distribution volume were 4.11 l h-1 70 kg-1 and 54.8 l 70 kg-1 respectively.,Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28771787/),[l] / [70·kg],54.8,176053,DB00776,Oxcarbazepine
,11436701,clearance (Cl/F),"The mean MHD clearance (Cl/F) calculated was 4.05 +/- 1.69 l/h, with a coefficient variation of 41%.",[Pharmacokinetic variability of oxcarbazepine in epileptic patients]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11436701/),[l] / [h],4.05,177429,DB00776,Oxcarbazepine
,11436701,half-life,The half-life of MHD was 10.50 +/- 3.17 hours.,[Pharmacokinetic variability of oxcarbazepine in epileptic patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11436701/),h,10.50,177430,DB00776,Oxcarbazepine
,7859804,apparent elimination half-life,The apparent elimination half-life of the monohydroxy-metabolite [19 (SD 3) h] in these patients was about twice that in healthy subjects.,The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7859804/),h,19,181564,DB00776,Oxcarbazepine
,17516704,apparent elimination half-life (t((1/2))),In plasma after a single oral administration of oxcarbazepine the mean apparent elimination half-life (t((1/2))) of MHD in adults was 8-9h.,Overview of the clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),h,8-9,197924,DB00776,Oxcarbazepine
,17516704,ki [inhibition constant],"In vitro, MHD inhibits the cytochrome P450 (CYP) 2C19 (ki [inhibition constant] = 88 micromol/L).",Overview of the clinical pharmacokinetics of oxcarbazepine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516704/),[μM] / [l],88,197925,DB00776,Oxcarbazepine
,25700977,volume of distribution,"The mean values of volume of distribution and clearance of MHD in the patients were 14.2 L and 2.38 L h(-1), respectively.",Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700977/),l,14.2,198924,DB00776,Oxcarbazepine
,25700977,clearance,"The mean values of volume of distribution and clearance of MHD in the patients were 14.2 L and 2.38 L h(-1), respectively.",Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700977/),[l] / [h],2.38,198925,DB00776,Oxcarbazepine
,10217343,terminal half-life (t1/2),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),h,2.2,206938,DB00776,Oxcarbazepine
,10217343,terminal half-life (t1/2),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),h,3.8,206939,DB00776,Oxcarbazepine
,10217343,clearance (CL),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),[l] / [h],7.8,206940,DB00776,Oxcarbazepine
,10217343,clearance (CL),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),[l] / [h],8.6,206941,DB00776,Oxcarbazepine
,10217343,Vd,The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),l,25,206942,DB00776,Oxcarbazepine
,10217343,Vd,The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),l,47,206943,DB00776,Oxcarbazepine
,10217343,Vd at steady state (V(ss)),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),,22.8,206944,DB00776,Oxcarbazepine
,10217343,Vd at steady state (V(ss)),The main pharmacokinetic parameters of R(-)- and S(+)-MHD were as follows: A terminal half-life (t1/2) of 2.2 +/- 0.4 hours for R(-)-MHD and of 3.8 +/- 0.3 hours for S(+)-MHD; a clearance (CL) of 7.8 +/- 1.3 L/h for R(-)-MHD and of 8.6 +/- 2.1 L/h for S(+)-MHD; a Vd of 25 +/- 6 L for R(-)-MHD and of 47 +/- 14 L for S(+)-MHD; and a Vd at steady state (V(ss)) of 22.8 +/- 3.6 for R(-)-MHD and of 29.9 +/- 4.1 for S(+)-MHD.,Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),,29.9,206945,DB00776,Oxcarbazepine
,10217343,absolute bioavailability,"After its oral administration to dogs, the absolute bioavailability was 78.4 +/- 20.9% for R(-)-MHD and 78.5 +/- 27.3% for S(+)-MHD; t1/2 was 2.7 +/- 0.6 hours for R(-)-MHD and 4.1 +/- 0.8 hours for S(+)-MHD.",Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),%,78.4,206946,DB00776,Oxcarbazepine
,10217343,absolute bioavailability,"After its oral administration to dogs, the absolute bioavailability was 78.4 +/- 20.9% for R(-)-MHD and 78.5 +/- 27.3% for S(+)-MHD; t1/2 was 2.7 +/- 0.6 hours for R(-)-MHD and 4.1 +/- 0.8 hours for S(+)-MHD.",Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),%,78.5,206947,DB00776,Oxcarbazepine
,10217343,t1/2,"After its oral administration to dogs, the absolute bioavailability was 78.4 +/- 20.9% for R(-)-MHD and 78.5 +/- 27.3% for S(+)-MHD; t1/2 was 2.7 +/- 0.6 hours for R(-)-MHD and 4.1 +/- 0.8 hours for S(+)-MHD.",Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),h,2.7,206948,DB00776,Oxcarbazepine
,10217343,t1/2,"After its oral administration to dogs, the absolute bioavailability was 78.4 +/- 20.9% for R(-)-MHD and 78.5 +/- 27.3% for S(+)-MHD; t1/2 was 2.7 +/- 0.6 hours for R(-)-MHD and 4.1 +/- 0.8 hours for S(+)-MHD.",Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217343/),h,4.1,206949,DB00776,Oxcarbazepine
,23758485,"Cmax,ss","Mean eslicarbazepine Cmax,ss (in μm) following ESL QD (87.3) was 33.3% higher (p < 0.05) compared to ESL BID (65.5) and 82.1% higher (p < 0.05) compared to OXC BID (48.0).",Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23758485/),μm,87.3,207252,DB00776,Oxcarbazepine
,23758485,"area under the curve (AUC)ss,0-τ","The mean area under the curve (AUC)ss,0-τ (in μmol h/L) following the last dose of an 8-day repeated dosing was 1156.3, 1117.6, and 968.4 for ESL QD, ESL BID, and OXC BID, respectively.",Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23758485/),[h·μM] / [l],1156.3,207253,DB00776,Oxcarbazepine
,23758485,"area under the curve (AUC)ss,0-τ","The mean area under the curve (AUC)ss,0-τ (in μmol h/L) following the last dose of an 8-day repeated dosing was 1156.3, 1117.6, and 968.4 for ESL QD, ESL BID, and OXC BID, respectively.",Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23758485/),[h·μM] / [l],1117.6,207254,DB00776,Oxcarbazepine
,23758485,"area under the curve (AUC)ss,0-τ","The mean area under the curve (AUC)ss,0-τ (in μmol h/L) following the last dose of an 8-day repeated dosing was 1156.3, 1117.6, and 968.4 for ESL QD, ESL BID, and OXC BID, respectively.",Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23758485/),[h·μM] / [l],968.4,207255,DB00776,Oxcarbazepine
,2591466,plasma elimination half-life,"The plasma elimination half-life of oxcarbazepine appeared to lie in the range 1.0-2.5 h, and that of its 10-hydroxy metabolite averaged 8.4 h.",First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591466/),h,1.0-2.5,208126,DB00776,Oxcarbazepine
,2591466,plasma elimination half-life,"The plasma elimination half-life of oxcarbazepine appeared to lie in the range 1.0-2.5 h, and that of its 10-hydroxy metabolite averaged 8.4 h.",First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591466/),h,8.4,208127,DB00776,Oxcarbazepine
,2591466,apparent oral clearance,The apparent oral clearance of the parent drug (averaging 2.51.kg-1.h-1) was high enough to suggest substantial presystemic elimination.,First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591466/),1/[h·kg],2.51,208128,DB00776,Oxcarbazepine
,33737678,trough,"For DRAE occurrence, the cut-off values of the MHD trough and AUC were 12.27 mg/L (specificity 0.570, sensitivity 0.643) and 698.5 mg h/L (specificity, sensitivity 0.571), respectively.",Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33737678/),[mg] / [l],12.27,214735,DB00776,Oxcarbazepine
,33737678,AUC,"For DRAE occurrence, the cut-off values of the MHD trough and AUC were 12.27 mg/L (specificity 0.570, sensitivity 0.643) and 698.5 mg h/L (specificity, sensitivity 0.571), respectively.",Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33737678/),[h·mg] / [l],698.5,214736,DB00776,Oxcarbazepine
,27003707,flow rate,"Chiral analysis in a run time of only 3 min was performed on an ACQUITY UPC(2) ™ Trefoil™ CEL2 column (3.0 × 150 mm, 2.5 μm) at 50 °C by isocratic elution with a mobile phase of supercritical carbon dioxide (purity ≥ 99.99%) and methanol (60:40, v/v) at a flow rate of 2.3 mL/min.",Development and validation of an enantioselective SFC-MS/MS method for simultaneous separation and quantification of oxcarbazepine and its chiral metabolites in beagle dog plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27003707/),[ml] / [min],2.3,215116,DB00776,Oxcarbazepine
,30169477,apparent clearance (CL/F),"In the final model, apparent clearance (CL/F) of LTG was estimated to be 1.48 L/h; 500 mg valproic acid, oxcarbazepine, and UGT2B7-161TT genotype changed the CL/F by -46.2, +31.1, and -21.8%, respectively.",A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30169477/),[l] / [h],1.48,216020,DB00776,Oxcarbazepine
,24887335,Ka,"The final PPK model of MHD was: Ka = 0.645 h⁻¹, V(L) = (11.3 + (age - 90.5) x 0.0282 + (TBW - 25.0) x 0.402) x e(0.0689), CL (L/h) = (0.557 + (DDPW - 20.8) x 0.00367 + (gender) x (-0.0636)) x e(0.120).",Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24887335/),h⁻¹,0.645,229938,DB00776,Oxcarbazepine
,21680153,apparent half-life,"The major compound in plasma was the active metabolite eslicarbazepine, which reached maximum concentrations (C(max)) 2h post-dose; thereafter, its plasma concentrations declined with a mean apparent half-life of 13, 14, and 20h in patients receiving ESL doses of 400, 800, and 1200mg once daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),h,13,230405,DB00776,Oxcarbazepine
,21680153,apparent half-life,"The major compound in plasma was the active metabolite eslicarbazepine, which reached maximum concentrations (C(max)) 2h post-dose; thereafter, its plasma concentrations declined with a mean apparent half-life of 13, 14, and 20h in patients receiving ESL doses of 400, 800, and 1200mg once daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),h,14,230406,DB00776,Oxcarbazepine
,21680153,apparent half-life,"The major compound in plasma was the active metabolite eslicarbazepine, which reached maximum concentrations (C(max)) 2h post-dose; thereafter, its plasma concentrations declined with a mean apparent half-life of 13, 14, and 20h in patients receiving ESL doses of 400, 800, and 1200mg once daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),h,20,230407,DB00776,Oxcarbazepine
,21680153,C(max),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μg] / [ml],9.7,230408,DB00776,Oxcarbazepine
,21680153,C(max),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μg] / [ml],15.5,230409,DB00776,Oxcarbazepine
,21680153,C(max),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μg] / [ml],23.0,230410,DB00776,Oxcarbazepine
,21680153,areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μgh] / [ml],132.5,230411,DB00776,Oxcarbazepine
,21680153,areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μgh] / [ml],205.4,230412,DB00776,Oxcarbazepine
,21680153,areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)),"Eslicarbazepine C(max) were 9.7, 15.5 and 23.0μg/mL, and areas under the plasma concentration-time curve over the dosing interval (AUC(0-24)) were 132.5, 205.4 and 336.1μgh/mL in patients receiving ESL doses of 400, 800 and 1200mg once-daily, respectively.",Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21680153/),[μgh] / [ml],336.1,230413,DB00776,Oxcarbazepine
,8827398,half-life,"When used as a monotherapy, topiramate is eliminated primarily in the urine in an unchanged form with a half-life of 20 to 30 hours; elimination is faster in patients receiving concurrent medication with enzyme-inducing anticonvulsants, in whom the extent of biotransformation becomes more prominent.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,20 to 30,232847,DB00776,Oxcarbazepine
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,50 to 70,232848,DB00776,Oxcarbazepine
,8827398,half-life,"It is rapidly absorbed, 50% bound to plasma proteins and is eliminated predominantly by biotransformation; zonisamide has a half-life of 50 to 70 hours in monotherapy patients, or 25 to 35 hours in patients comedicated with enzyme-inducing anticonvulsants.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,25 to 35,232849,DB00776,Oxcarbazepine
,8827398,half-life,"It is highly (96%) bound to plasma proteins and it is eliminated primarily by cytochrome P450 3A-mediated oxidation, with a half-life of about 7 hours in healthy volunteers.","The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8827398/),h,7,232850,DB00776,Oxcarbazepine
,22246398,serum concentration,The mean ± SD serum concentration of OHC was 14.47 ± 8.28 μg/mL at a mean daily dose of 16.22 ± 7.99 mg/kg.,Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22246398/),[μg] / [ml],14.47,235025,DB00776,Oxcarbazepine
,10368079,areas under the plasma concentration curves (AUC(0-24h,"Compared with placebo, areas under the plasma concentration curves (AUC(0-24h, geometric means) decreased by 47% for both EE (from 1,677 to 886 pg.h/ml; p < 0.01) and LN (from 137 to 73 ng.h/ml; p < 0.01), during OCBZ treatment.",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[h·pg] / [ml],1,245147,DB00776,Oxcarbazepine
,10368079,areas under the plasma concentration curves (AUC(0-24h,"Compared with placebo, areas under the plasma concentration curves (AUC(0-24h, geometric means) decreased by 47% for both EE (from 1,677 to 886 pg.h/ml; p < 0.01) and LN (from 137 to 73 ng.h/ml; p < 0.01), during OCBZ treatment.",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[h·ng] / [ml],137,245148,DB00776,Oxcarbazepine
,10368079,Peak plasma EE concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[pg] / [ml],180,245149,DB00776,Oxcarbazepine
,10368079,Peak plasma EE concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[pg] / [ml],117,245150,DB00776,Oxcarbazepine
,10368079,peak plasma LN concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[ng] / [ml],10.2,245151,DB00776,Oxcarbazepine
,10368079,peak plasma LN concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[ng] / [ml],7.7,245152,DB00776,Oxcarbazepine
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,13,245153,DB00776,Oxcarbazepine
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,28.8,245154,DB00776,Oxcarbazepine
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,15,245155,DB00776,Oxcarbazepine
,22612290,"half-life (t(1/2,eff) )","After ESL oral administration, the effective half-life (t(1/2,eff) ) of eslicarbazepine was 20-24 h, which is approximately two times longer than its terminal half-life (t(1/2)).",Pharmacokinetics and drug interactions of eslicarbazepine acetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612290/),h,20-24,249977,DB00776,Oxcarbazepine
,6650125,Tmax,The time-concentration curves showed a median Tmax of 8 h followed by a plateau until 24 h indicating saturable kinetic processes.,"Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650125/),h,8,251989,DB00776,Oxcarbazepine
,6650125,half-life,"The half-life of 10-OH-carbazepine in saliva, 13.8 +/- 3.7 (SD) h, was significantly shorter than in serum, 19.3 +/- 6.2 (SD) h.","Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650125/),h,13.8,251990,DB00776,Oxcarbazepine
,6650125,half-life,"The half-life of 10-OH-carbazepine in saliva, 13.8 +/- 3.7 (SD) h, was significantly shorter than in serum, 19.3 +/- 6.2 (SD) h.","Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6650125/),h,19.3,251991,DB00776,Oxcarbazepine
,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,253,254137,DB00776,Oxcarbazepine
>,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,208,254138,DB00776,Oxcarbazepine
,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,255,254139,DB00776,Oxcarbazepine
>,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,194,254140,DB00776,Oxcarbazepine
>,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,247,254141,DB00776,Oxcarbazepine
>,17869472,m/z,"The MS-MS ion transition monitored were m/z 253>208 for OXC, m/z 255>194 for MHD and m/z 247>204 for IS.","Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17869472/),,204,254142,DB00776,Oxcarbazepine
,24571554,clearance,Mean study population value of LTG clearance estimated by the final model was 3.17 l/h.,Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],3.17,259257,DB00776,Oxcarbazepine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],4.02,259258,DB00776,Oxcarbazepine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],3.03,259259,DB00776,Oxcarbazepine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],4.95,259260,DB00776,Oxcarbazepine
,24571554,clearance,"A significant influence of OC comedication on LTG clearance was seen in both LTG monotherapy (clearance with OC 4.02±0.38 l/h, OC-free week 3.03±0.39 l/h) and in LTG-CBZ combination (clearance with OC 4.95±0.15 l/h, OC-free week 4.15±0.26 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],4.15,259261,DB00776,Oxcarbazepine
,24571554,clearance,"No influence of OC was found in LTG-VPA combination (clearance with OC 0.99±0.16 l/h, OC-free week 0.90±0.15 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],0.99,259262,DB00776,Oxcarbazepine
,24571554,clearance,"No influence of OC was found in LTG-VPA combination (clearance with OC 0.99±0.16 l/h, OC-free week 0.90±0.15 l/h).",Effect of oral contraceptives on lamotrigine levels depends on comedication. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24571554/),[l] / [h],0.90,259263,DB00776,Oxcarbazepine
,7993989,areas under the plasma concentration-time curves (AUC),"Mean (+/- SD) areas under the plasma concentration-time curves (AUC) of the major component in plasma, the active monohydroxy metabolite (MHD), which is responsible for the therapeutic effect in man, were 672 (25) mumol L-1 h when given to the fasted volunteers and 780 (31) mumol L-1 h (p = 0.042) when given after a substantial breakfast.",The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7993989/),[h·μM] / [l],672,269580,DB00776,Oxcarbazepine
,7993989,areas under the plasma concentration-time curves (AUC),"Mean (+/- SD) areas under the plasma concentration-time curves (AUC) of the major component in plasma, the active monohydroxy metabolite (MHD), which is responsible for the therapeutic effect in man, were 672 (25) mumol L-1 h when given to the fasted volunteers and 780 (31) mumol L-1 h (p = 0.042) when given after a substantial breakfast.",The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7993989/),[h·μM] / [l],780,269581,DB00776,Oxcarbazepine
,7993989,maximum concentrations (Cmax),Mean (+/- SD) maximum concentrations (Cmax) were 25.5 (4.8) mumol L-1 when given to the fasted volunteers and 31.4 (5.3) mumol L-1 (p = 0.025) when given after breakfast.,The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7993989/),[μM] / [l],25.5,269582,DB00776,Oxcarbazepine
,7993989,maximum concentrations (Cmax),Mean (+/- SD) maximum concentrations (Cmax) were 25.5 (4.8) mumol L-1 when given to the fasted volunteers and 31.4 (5.3) mumol L-1 (p = 0.025) when given after breakfast.,The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7993989/),[μM] / [l],31.4,269583,DB00776,Oxcarbazepine
,12915337,half-life,"Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response.",The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915337/),h,6 to 8,271378,DB00776,Oxcarbazepine
